The Oxford COVID-19 vaccine is 'progressing very well,' according to the lead scientists, who said 10,000 more people will be inoculated
Advertisement
Bill Bostock
May 22, 2020, 15:55 IST
The Radcliffe Camera, part of the main library at Oxford University, England.Wikimedia Commons
The head of the Oxford Vaccine Group said Friday that clinic trials on its vaccine for the coronavirus are "progressing very well."
1,000 people have already been inoculated. The next stage will see 10,000 more given the treatment through May and June, Andrew Pollard said.
The trial vaccine is called as AZD1222 or ChAdOx1 nCoV-19. It was first tested on humans on April 23, following success in macaque monkeys.
The group said they hoped for clinical test results in two months, but that it could take as long as six.
Advertisement
The head of the Oxford Vaccine Group said Friday that its clinical trials are "progressing very well" and that the program will inoculate 10,000 new people.
"We are now initiating studies to evaluate how well the vaccine induces immune responses in older adults," Professor Andrew Pollard, head of the Oxford Vaccine Group, said in a press release.
1,000 people have since been given the trial vaccine across the UK, but children and those over 55 were excluded.
Advertisement
10,260 new people, including the elderly, will be given the trial vaccine in May and June, the group said. Subjects keep a diary and submit regular blood samples.
The group said that results would be available "in a couple of months," but that "it could take up to six months" depending on outside factors.
Progress could be slowed if the UK coronavirus outbreak slows down, because it means fewer test subjects will be exposed naturally to the virus.
To mitigate this potential issue, the group is prioritizing volunteers with "a higher chance of being exposed," like frontline healthcare workers.
Advertisement
The Oxford Vaccine Group is one of a few elite laboratories and facilities leading the race to find a vaccine.
"The decision — at our own risk and cost — has been solely taken to get a jump-start on manufacturing," CEO Adar Poonawalla said.
Despite the progress, there are concerns that even when a vaccine becomes available, a global rollout will be hampered by a shortage of the glass vials and lids necessary to distribute the product.
NewsletterSIMPLY PUT - where we join the dots to inform and inspire you. Sign up for a weekly brief collating many news items into one untangled thought delivered straight to your mailbox.